Immunoglobulin_NN G_NN Antibody_NN against_IN Helicobacter_NP pylori_NNS :_: Clinical_JJ Implications_NNS of_IN Levels_NP Found_NP in_IN Serum_NP The_DT clinical_JJ significance_NN of_IN high_JJ levels_NNS of_IN antibody_NN against_IN Helicobacter_NP pylori_NNS is_VBZ still_RB unclear_JJ ._SENT We_PP sought_VBD to_TO evaluate_VB whether_IN the_DT serum_NN antibody_NN levels_NNS could_MD predict_VB the_DT presence_NN of_IN macroscopic_JJ gastroduodenal_JJ disease_NN ,_, to_TO identify_VB factors_NNS that_WDT correlate_VBP with_IN antibody_NN levels_NNS in_IN a_DT multivariate_JJ context_NN ,_, and_CC to_TO determine_VB the_DT predictive_JJ value_NN of_IN antibody_NN levels_NNS for_IN diagnosing_VBG H._NP pylori_NNS infection_NN ._SENT The_DT grades_NNS of_IN gastritis_NN and_CC density_NN of_IN H._NP pylori_NNS colonization_NN were_VBD scored_VBN separately_RB using_VBG the_DT updated_VBN Sydney_NP system_NN for_IN antral_NN and_CC body_NN mucosa_NN ._SENT An_DT enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) for_IN the_DT quantitative_JJ detection_NN in_IN serum_NN of_IN IgG_NP antibodies_NNS to_TO H._NP pylori_NNS was_VBD performed_VBN ._SENT Of_IN the_DT 170_CD dyspeptic_JJ patients_NNS ,_, 105_CD (_( 62_CD %_NN )_) had_VBD H._NP pylori_NNS infection_NN ._SENT There_EX was_VBD no_DT difference_NN in_IN antibody_NN levels_NNS among_IN endoscopic_JJ findings_NNS of_IN normal_JJ mucosa_NN ,_, chronic_JJ gastritis_NN ,_, and_CC duodenal_JJ ulcer_NN ._SENT On_IN multivariate_JJ linear_JJ regression_NN analysis_NN ,_, the_DT status_NN of_IN H._NP pylori_NNS infection_NN ,_, mononuclear_JJ cell_NN infiltration_NN of_IN body_NN mucosa_NN ,_, and_CC age_NN correlated_VBN with_IN antibody_NN levels_NNS ._SENT The_DT negative_JJ predictive_JJ value_NN for_IN antibody_NN levels_NNS of_IN <30_U/ml 70_CD U/ml_NN is_VBZ 98_CD %_NN ._SENT We_PP conclude_VBP that_IN serum_NN antibody_NN levels_NNS do_VBP not_RB predict_VB the_DT severity_NN of_IN gastroduodenal_JJ diseases_NNS or_CC the_DT density_NN of_IN H._NP pylori_NNS colonization_NN in_IN H._NP pylori-infected_JJ dyspeptic_JJ patients_NNS ._SENT Higher_JJR levels_NNS are_VBP associated_VBN with_IN the_DT presence_NN of_IN H._NP pylori_NNS infection_NN ,_, the_DT chronic_JJ gastritis_NN score_NN of_IN the_DT corpus_NN ,_, and_CC older_JJR age_NN ._SENT Setting_VBG a_DT gray_JJ zone_NN is_VBZ necessary_JJ for_IN ELISA_NP ,_, since_IN the_DT accuracy_NN in_IN this_DT zone_NN does_VBZ not_RB allow_VB a_DT precise_JJ determination_NN of_IN H._NP pylori_NNS status_NN ._SENT Helicobacter_NN pylori_NNS has_VBZ been_VBN established_VBN as_IN an_DT important_JJ etiological_JJ factor_NN for_IN chronic_JJ gastritis_NN and_CC duodenal_JJ ulcer_NN ._SENT It_PP is_VBZ also_RB associated_VBN with_IN gastric_JJ ulcer_NN and_CC gastric_JJ cancer_NN ._SENT As_IN the_DT test-and-treat_JJ policy_NN for_IN H._NP pylori_NNS infection_NN is_VBZ gradually_RB being_VBG accepted_VBN by_IN general_JJ practitioners_NNS ,_, a_DT simple_JJ ,_, reliable_JJ ,_, and_CC noninvasive_JJ diagnostic_JJ test_NN for_IN H._NP pylori_NNS has_VBZ become_VBN essential_JJ in_IN clinical_JJ practice_NN ._SENT An_DT easier_JJR and_CC cheaper_JJR way_NN to_TO diagnose_VB H._NP pylori_NNS infection_NN noninvasively_RB is_VBZ to_TO test_VB for_IN antibodies_NNS to_TO the_DT infection_NN ._SENT Enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) has_VBZ been_VBN the_DT most_RBS commonly_RB used_VBN serological_JJ test_NN because_IN it_PP is_VBZ suited_VBN for_IN screening_VBG large_JJ populations_NNS ._SENT Clinically_RB ,_, some_DT patients_NNS are_VBP very_RB concerned_VBN about_IN contracting_VBG H._NP pylori_NNS infection_NN when_WRB they_PP are_VBP told_VBN they_PP have_VBP high_JJ antibody_NN levels_NNS ._SENT However_RB ,_, the_DT clinical_JJ significance_NN of_IN the_DT levels_NNS is_VBZ still_RB unclear_JJ ._SENT The_DT correlation_NN between_IN anti-H_NP ._SENT pylori_NNS antibody_NN levels_NNS and_CC the_DT severity_NN of_IN histological_JJ gastritis_NN or_CC H._NP pylori_NNS density_NN has_VBZ been_VBN studied_VBN with_IN conflicting_JJ results_NNS ._SENT This_DT discrepancy_NN in_IN results_NNS may_MD arise_VB from_IN differences_NNS in_IN classification_NN and_CC grading_VBG of_IN gastritis_NN ,_, the_DT numbers_NNS of_IN subjects_NNS ,_, consideration_NN of_IN confounding_VBG factors_NNS ,_, and_CC statistical_JJ methods_NNS ._SENT One_CD study_NN reported_VBD that_IN immunoglobulin_NN G_NP (_( IgG_NP )_) antibody_NN levels_NNS correlated_VBN with_IN the_DT grades_NNS of_IN antral_JJ polymorphonuclear_JJ leukocyte_NN infiltration_NN and_CC antral_JJ bacterial_JJ density_NN ,_, while_IN another_DT study_NN demonstrated_VBD that_IN having_VBG higher_JJR levels_NNS implies_VBZ advanced_JJ antral_JJ gastritis_NN with_IN either_DT acute_JJ or_CC chronic_JJ inflammation_NN ._SENT Both_DT studies_NNS concluded_VBD that_IN levels_NNS in_IN themselves_PP do_VBP not_RB provide_VB a_DT method_NN for_IN predicting_VBG the_DT presence_NN of_IN an_DT ulcer_NN ._SENT However_RB ,_, the_DT sample_NN size_NN was_VBD small_JJ in_IN one_CD study_NN ,_, and_CC no_DT body_NN mucosa_NN was_VBD evaluated_VBN in_IN either_DT study_NN ._SENT Therefore_RB ,_, we_PP conducted_VBD this_DT study_NN to_TO identify_VB which_WDT factors_NNS correlate_VBP with_IN antibody_NN levels_NNS in_IN a_DT multivariate_JJ context_NN and_CC to_TO determine_VB if_IN antibody_NN levels_NNS could_MD predict_VB the_DT presence_NN of_IN macroscopic_JJ gastroduodenal_JJ disease_NN ._SENT The_DT predictive_JJ value_NN of_IN antibody_NN levels_NNS for_IN diagnosing_VBG H._NP pylori_NNS infection_NN was_VBD also_RB evaluated_VBN ._SENT Dyspeptic_JJ patients_NNS who_WP were_VBD scheduled_VBN for_IN upper_JJ gastrointestinal_JJ endoscopy_NN were_VBD recruited_VBN into_IN the_DT study_NN ._SENT Patients_NNS with_IN any_DT of_IN the_DT following_VBG conditions_NNS were_VBD excluded_VBN :_: (_( i_NP )_) ulcer_NN complications_NNS ,_, such_JJ as_IN bleeding_NN ,_, stenosis_NN ,_, or_CC perforation_NN ;_: (_( ii_NP )_) previous_JJ stomach_NN surgery_NN ;_: (_( iii_NP )_) intake_NN of_IN any_DT substitute_NN for_IN benzimidazoles_NNS or_CC preparations_NNS containing_VBG bismuth_NN within_IN 1_CD month_NN prior_JJ to_TO administration_NN of_IN the_DT test_NN ;_: or_CC (_( iv_NN )_) having_VBG been_VBN treated_VBN with_IN or_CC currently_RB on_IN anti-H_NP ._SENT pylori_NNS therapy_NN ._SENT For_IN serology_NN studies_NNS ,_, blood_NN was_VBD drawn_VBN immediately_RB after_IN endoscopy_NN ,_, and_CC sera_NN were_VBD collected_VBN and_CC stored_VBN at_IN -70C_NN until_IN they_PP were_VBD assayed_VBN ._SENT Histology_NN ._SENT |_SYM During_IN endoscopy_NN ,_, two_CD sets_NNS of_IN biopsy_NN specimens_NNS from_IN the_DT antrum_NN and_CC the_DT greater_JJR curvature_NN of_IN the_DT midbody_NN were_VBD obtained_VBN for_IN rapid_JJ urease_NN testing_NN (_( CLO_NP Test_NP ;_: Delta_NP West_NP ,_, Bentley_NP ,_, Australia_NP )_) and_CC histology_NN ._SENT Hematoxylin_NN and_CC eosin_NN stains_NNS were_VBD used_VBN to_TO grade_VB the_DT gastritis_NN ._SENT The_DT grades_NNS of_IN gastritis_NN were_VBD assessed_VBN for_IN infiltration_NN of_IN mononuclear_JJ cells_NNS or_CC neutrophils_NNS ,_, mucosal_JJ atrophy_NN ,_, and_CC intestinal_JJ metaplasia_NN using_VBG visual_JJ analogue_NN scales_NNS described_VBN in_IN the_DT updated_VBN Sydney_NP system_NN on_IN a_DT four-point_NN scale_NN (_( 0_CD ,_, normal_RB ;_: 1_LS ,_, mild_JJ ;_: 2_LS ,_, moderate_JJ ;_: and_CC 3_CD ,_, marked_JJ )_) ._SENT A_DT modified_JJ Giemsa_NP stain_NN was_VBD used_VBN to_TO assess_VB the_DT density_NN of_IN H._NP pylori_NNS ._SENT The_DT number_NN of_IN lymphoid_JJ follicles_NNS was_VBD recorded_VBN ._SENT All_DT histological_JJ sections_NNS were_VBD evaluated_VBN by_IN the_DT same_JJ pathologist_NN ,_, who_WP was_VBD blinded_VBN to_TO the_DT patients_NNS '_POS clinical_JJ conditions_NNS ._SENT Quantitative_JJ ELISA_NP ._SENT |_SYM Serum_NP specimens_NNS were_VBD tested_VBN for_IN the_DT presence_NN of_IN IgG_NP antibodies_NNS against_IN H._NP pylori_NNS using_VBG a_DT quantitative_JJ ELISA_NP (_( HEL-pTEST_NP II_NP ;_: AMRAD_NP ,_, Kew_NP ,_, Australia_NP )_) ._SENT Reference_NN standards_NNS were_VBD used_VBN to_TO produce_VB a_DT standard_JJ curve_NN to_TO quantitate_VB H._NP pylori_NNS antibody_NN levels_NNS in_IN patient_JJ samples_NNS ._SENT The_DT results_NNS were_VBD expressed_VBN in_IN arbitrary_JJ units_NNS per_IN milliliter_NN ._SENT The_DT antigen_NN was_VBD an_DT inactivated_VBN native_JJ antigen_NN of_IN H._NP pylori_NNS ._SENT On_IN the_DT day_NN of_IN testing_NN ,_, we_PP added_VBD 100_CD mul_NN of_IN diluted_JJ specimens_NNS ,_, diluted_VBN positive_JJ and_CC negative_JJ controls_NNS ,_, and_CC duplicates_NNS of_IN reference_NN standards_NNS 1_CD to_TO 4_CD to_TO the_DT appropriate_JJ wells_NNS of_IN the_DT microtiter_NN plate_NN ._SENT The_DT plate_NN was_VBD incubated_VBN for_IN 15_CD min_NN at_IN room_NN temperature_NN and_CC then_RB washed_VBN six_CD times_NNS with_IN a_DT wash_NN buffer_NN ._SENT After_IN the_DT washing_NN ,_, 100_CD mul_NN of_IN sheep_NN anti-human_NP IgG_NP conjugated_VBD to_TO horseradish_NN peroxidase_NN was_VBD added_VBN to_TO each_DT well_NN ._SENT After_IN a_DT further_JJR 15_CD min_NN of_IN incubation_NN ,_, 100_CD mul_NN of_IN substrate_NN reagent_NN was_VBD added_VBN to_TO each_DT well_RB and_CC incubated_VBN in_IN the_DT dark_NN for_IN 15_CD min_NN at_IN room_NN temperature_NN ._SENT Then_RB ,_, stopping_VBG solution_NN (_( 100_CD mul_NN of_IN H2SO4_NP )_) was_VBD added_VBN to_TO each_DT well_NN to_TO terminate_VB the_DT enzymatic_JJ reaction_NN ._SENT The_DT absorbance_NN was_VBD read_VBN within_IN 30_CD min_NN using_VBG a_DT 450-nm-pore-size_JJ filter_NN with_IN a_DT 620-nm-pore-size_JJ filter_NN as_IN a_DT reference_NN ._SENT H._NP pylori_NNS status_NN ._SENT |_SYM A_DT patient_NN was_VBD classified_VBN as_IN H._NP pylori_NNS infected_VBN if_IN both_CC the_DT CLO_NP and_CC histological_JJ tests_NNS were_VBD positive_JJ ._SENT A_DT patient_NN was_VBD classified_VBN as_IN non-H_NP ._SENT pylori-infected_JJ if_IN both_DT methods_NNS were_VBD negative_JJ ._SENT Patients_NNS who_WP had_VBD only_RB one_CD positive_JJ CLO_NP or_CC histology_NN test_NN were_VBD considered_VBN to_TO be_VB of_IN indeterminate_JJ status_NN ._SENT Statistical_JJ analysis_NN ._SENT |_SYM Continuous_JJ data_NNS were_VBD analyzed_VBN by_IN the_DT two-tailed_JJ Student_NN 's_POS t_NN test_NN or_CC analysis_NN of_IN variance_NN (_( ANOVA_NP )_) ._SENT When_WRB ANOVA_NP of_IN multiple_JJ groups_NNS revealed_VBD a_DT difference_NN at_IN the_DT 5_CD %_NN level_NN ,_, the_DT post_NN hoc_FW multiple-comparison_NN technique_NN was_VBD used_VBN to_TO determine_VB which_WDT pairs_NNS of_IN groups_NNS were_VBD responsible_JJ for_IN the_DT overall_JJ difference_NN ._SENT Spearman_NP 's_POS rank_JJ correlation_NN was_VBD used_VBN to_TO examine_VB the_DT relationship_NN between_IN antibody_NN levels_NNS and_CC grades_NNS of_IN gastritis_NN ._SENT Multiple_JJ stepwise_JJ linear_JJ regression_NN was_VBD also_RB used_VBN to_TO identify_VB which_WDT factors_NNS were_VBD related_VBN to_TO the_DT antibody_NN levels_NNS ._SENT The_DT data_NNS were_VBD processed_VBN using_VBG SPSS_NP software_NN ._SENT Positive_JJ and_CC negative_JJ predictive_JJ values_NNS were_VBD calculated_VBN for_IN the_DT ELISA_NP (_( HEL-pTEST_NP II_NP )_) ,_, using_VBG gastric_JJ biopsy_NN results_NNS as_IN the_DT "_`` gold_JJ standard_NN ._SENT "_'' One_CD hundred_CD and_CC seventy_CD patients_NNS (_( 88_CD men_NNS and_CC 82_CD women_NNS ;_: mean_VB age_NN +-_NN standard_JJ deviation_NN [_SYM SD_NP ]_SYM ,_, 43.7_CD +-_NN 13.5_CD )_) were_VBD included_VBN in_IN the_DT study_NN ._SENT There_EX were_VBD 34_CD patients_NNS with_IN normal_JJ endoscopic_JJ findings_NNS ,_, 62_CD patients_NNS with_IN gastritis_NN ,_, 57_CD patients_NNS with_IN duodenal_JJ ulcers_NNS ,_, 5_CD patients_NNS with_IN gastric_JJ ulcers_NNS ,_, 2_CD patients_NNS with_IN combined_JJ gastric_JJ and_CC duodenal_JJ ulcers_NNS ,_, and_CC 10_CD patients_NNS with_IN other_JJ findings_NNS ._SENT Based_VBN on_IN the_DT proposed_VBN gold_NN standard_NN ,_, 105_CD patients_NNS were_VBD infected_JJ ,_, 64_CD were_VBD not_RB infected_VBN ,_, and_CC 1_CD was_VBD of_IN indeterminate_JJ status_NN ._SENT Anti-H_NN ._SENT pylori_NNS antibody_NN levels_NNS did_VBD not_RB show_VB a_DT normal_JJ distribution_NN (_( skewness_NN ,_, 1.888_CD ;_: kurtosis_NN ,_, 2.839_CD )_) ,_, but_CC its_PP$ logarithm_NN did_VBD (_( skewness_NN ,_, 0.033_CD ;_: kurtosis_NN ,_, -0.967_CD )_) ,_, so_RB logarithmic_JJ transformation_NN was_VBD performed_VBN in_IN the_DT assessment_NN of_IN anti-H_NP ._SENT pylori_NNS antibody_NN levels_NNS during_IN the_DT two-tailed_JJ Student_NN 's_POS t-test_NN or_CC ANOVA_NP by_IN Scheffe_NP 's_POS method_NN or_CC a_DT linear_JJ regression_NN ._SENT There_EX was_VBD no_DT difference_NN in_IN antibody_NN levels_NNS between_IN men_NNS and_CC women_NNS or_CC smokers_NNS and_CC nonsmokers_NNS or_CC among_IN different_JJ blood_NN groups_NNS ._SENT The_DT influence_NN of_IN drinking_VBG habits_NNS on_IN antibody_NN levels_NNS was_VBD not_RB evaluated_VBN because_IN only_RB six_CD patients_NNS were_VBD regular_JJ drinkers_NNS ._SENT For_IN dyspeptic_JJ patients_NNS with_IN H._NP pylori_NNS infection_NN ,_, there_EX was_VBD no_DT difference_NN in_IN antibody_NN levels_NNS among_IN the_DT endoscopic_JJ findings_NNS for_IN the_DT normal_JJ mucosa_NN (_( n_NN =_SYM 12_CD )_) ,_, chronic_JJ gastritis_NN (_( n_NN =_SYM 36_CD )_) ,_, and_CC duodenal_JJ ulcers_NNS (_( n_NN =_SYM 46_CD )_) (_( 223_CD +-_NN 220_CD ,_, 227_CD +-_NN 223_CD ,_, and_CC 228_CD +-_NN 196_CD U/ml_NN [_SYM mean_JJ +-_JJ SD_NN ]_SYM ,_, respectively_RB ;_: P_NN =_SYM 0.99_CD )_) ._SENT The_DT mean_JJ serum_NN anti-H_NN ._SENT pylori_NNS antibody_NN levels_NNS in_IN relation_NN to_TO the_DT grading_VBG of_IN the_DT four_CD histological_JJ features_NNS of_IN the_DT antral_JJ mucosa_NN and_CC body_NN mucosa_NN are_VBP illustrated_VBN in_IN Fig._NN and_CC ,_, respectively_RB ._SENT We_PP see_VBP a_DT trend_NN for_IN the_DT mean_JJ antibody_NN levels_NNS to_TO rise_VB as_IN the_DT grades_NNS of_IN gastritis_NN and_CC H._NP pylori_NNS density_NN increase_NN ._SENT Significant_JJ correlations_NNS were_VBD found_VBN between_IN the_DT antibody_NN levels_NNS and_CC the_DT grades_NNS of_IN gastritis_NN in_IN the_DT antral_JJ mucosa_NN (_( Spearman_NP 's_POS rank_JJ correlation_NN :_: r_SYM =_SYM 0.586_CD and_CC P_NN <_SYM 0.001_CD for_IN neutrophil_JJ infiltration_NN ,_, r_LS =_SYM 0.620_CD and_CC P_NN <_SYM 0.001_CD for_IN mononuclear_JJ cell_NN infiltration_NN ,_, r_LS =_SYM 0.429_CD and_CC P_NN <_SYM 0.001_CD for_IN atrophy_NN ,_, r_LS =_SYM 0.630_CD and_CC P_NN <_SYM 0.001_CD for_IN H._NP pylori_NNS density_NN ,_, and_CC r_LS =_SYM 0.438_CD and_CC P_NN <_SYM 0.001_CD for_IN lymphoid_JJ follicles_NNS )_) and_CC in_IN the_DT body_NN mucosa_NN (_( Spearman_NP 's_POS rank_JJ correlation_NN :_: r_SYM =_SYM 0.598_CD and_CC P_NN <_SYM 0.001_CD for_IN neutrophil_JJ infiltration_NN ,_, r_LS =_SYM 0.618_CD and_CC P_NN <_SYM 0.001_CD for_IN mononuclear_JJ cell_NN infiltration_NN ,_, r_LS =_SYM 0.481_CD and_CC P_NN <_SYM 0.001_CD for_IN atrophy_NN ,_, r_LS =_SYM 0.680_CD and_CC P_NN <_SYM 0.001_CD for_IN H._NP pylori_NNS density_NN ,_, and_CC r_LS =_SYM 0.190_CD and_CC P_NN <_SYM 0.05_CD for_IN lymphoid_JJ follicles_NNS )_) ._SENT However_RB ,_, if_IN the_DT calculation_NN was_VBD restricted_VBN to_TO H._NP pylori-infected_JJ patients_NNS ,_, only_RB the_DT grades_NNS of_IN neutrophil_JJ infiltration_NN and_CC mononuclear_JJ cell_NN infiltration_NN ,_, atrophy_NN ,_, and_CC the_DT number_NN of_IN lymphoid_JJ follicles_NNS in_IN the_DT body_NN mucosa_NN retained_VBD significant_JJ correlation_NN with_IN antibody_NN levels_NNS (_( r_LS =_SYM 0.248_CD and_CC P_NN <_SYM 0.05_CD ,_, r_NN =_SYM 0.292_CD and_CC P_NN <_SYM 0.005_CD ,_, r_NN =_SYM 0.218_CD and_CC P_NN <_SYM 0.05_CD ,_, and_CC r_LS =_SYM 0.230_CD and_CC P_NN <_SYM 0.05_CD ,_, respectively_RB )_) ._SENT This_DT is_VBZ also_RB noted_VBN in_IN estimating_VBG correlation_NN between_IN antibody_NN levels_NNS and_CC age_NN ._SENT Significant_JJ correlations_NNS were_VBD found_VBN when_WRB all_DT subjects_NNS were_VBD considered_VBN (_( Spearman_NP 's_POS rank_JJ correlation_NN :_: r_SYM =_SYM 0.200_CD ;_: P_NN <_0.01), =45_NN years_NNS )_) and_CC younger_JJR (_( <45_NN years_NNS )_) groups_NNS ,_, the_DT difference_NN in_IN antibody_NN levels_NNS between_IN the_DT two_CD groups_NNS in_IN H._NP pylori-positive_JJ patients_NNS approached_VBD significance_NN (_( median_JJ ,_, 164_CD ,_, and_CC range_NN ,_, 38_CD to_TO 823_CD versus_CC 124_CD and_CC 21_CD to_TO 804_CD ;_: P_NN =_SYM 0.09_CD )_) ._SENT Intestinal_JJ metaplasia_NN in_IN antral_JJ specimens_NNS was_VBD observed_VBN in_IN 18_CD patients_NNS (_( 15_CD with_IN score_NN 2_CD ,_, 2_CD with_IN score_NN 3_CD ,_, and_CC 1_CD with_IN score_NN 4_CD )_) ,_, so_RB scores_NNS 2_CD ,_, 3_CD ,_, and_CC 4_CD were_VBD grouped_VBN together_RB ._SENT There_EX was_VBD no_DT difference_NN in_IN the_DT mean_JJ antibody_NN levels_NNS between_IN patients_NNS with_IN and_CC without_IN intestinal_JJ metaplasia_NN (_( P_NN =_SYM 0.984_CD )_) ._SENT No_DT intestinal_JJ metaplasia_NN was_VBD observed_VBN in_IN the_DT body_NN specimens_NNS ._SENT A_DT multiple_JJ stepwise_JJ linear_JJ regression_NN was_VBD performed_VBN to_TO analyze_VB the_DT relationship_NN between_IN antibody_NN levels_NNS and_CC the_DT following_VBG predictors_NNS :_: sex_NN ,_, age_NN ,_, smoking_NN ,_, blood_NN groups_NNS ,_, grades_NNS of_IN antral_NN and_CC body_NN gastritis_NN ,_, number_NN of_IN lymphoid_JJ follicles_NNS ,_, H._NP pylori_NNS density_NN ,_, and_CC status_NN of_IN H._NP pylori_NNS infection_NN ._SENT Table_NN shows_VBZ that_IN the_DT status_NN of_IN H._NP pylori_NNS infection_NN ,_, grade_NN of_IN mononuclear_JJ cell_NN infiltration_NN of_IN body_NN mucosa_NN ,_, and_CC age_NN were_VBD three_CD independent_JJ factors_NNS correlated_VBN with_IN antibody_NN levels_NNS (_( R_NP =_SYM 0.780_CD ;_: R2_NP =_SYM 0.608_CD )_) ._SENT Figure_NN shows_VBZ the_DT distribution_NN of_IN anti-H_NP ._SENT pylori_NNS antibody_NN (_( IgG_NP )_) levels_NNS in_IN H._NP pylori-infected_JJ and_CC uninfected_JJ patients_NNS (_( n_NN =_SYM 169_CD )_) ._SENT The_DT negative_JJ predictive_JJ value_NN of_IN antibody_NN levels_NNS of_IN <20_NP U/ml_NP is_VBZ 100_CD %_NN ,_, and_CC that_IN for_IN levels_NNS of_IN <30_is 70_CD U/ml_NN is_VBZ 98_CD %_NN ._SENT There_EX were_VBD 27_CD patients_NNS (_( 16_CD %_NN )_) whose_WP$ antibody_NN levels_NNS fell_VBD between_IN 30_CD and_CC 70_CD U/ml_NN ._SENT Among_IN them_PP ,_, 14_CD patients_NNS were_VBD H._NP pylori_NNS infected_VBD and_CC the_DT rest_NN were_VBD non-H_NP ._SENT pylori_NNS infected_VBN ,_, judged_VBN by_IN the_DT reference_NN standards_NNS ._SENT This_DT suggests_VBZ that_IN little_RB more_JJR than_IN a_DT guess_NN is_VBZ involved_VBN when_WRB making_VBG a_DT positive-negative_JJ decision_NN in_IN this_DT gray_JJ zone_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Comparison_NN of_IN serum_NN anti-H_NN ._SENT pylori_NNS Comparison_NN of_IN serum_NN anti-H_NN ._SENT pylori_NNS antibody_NN (_( IgG_NP )_) levels_NNS among_IN groups_NNS based_VBN on_IN grading_VBG scores_NNS of_IN four_CD histological_JJ features_NNS of_IN antral_JJ mucosa_NN ._SENT Scores_NNS :_: 0_CD ,_, normal_RB ;_: 1_LS ,_, mild_JJ ;_: 2_LS ,_, moderate_JJ ;_: and_CC 3_CD ,_, marked_VBD ._SENT Each_DT column_NN represents_VBZ the_DT mean_JJ +-_NN standard_JJ error_NN of_IN the_DT mean_NN ._SENT **_SYM ,_, P_NN <_SYM 0.01_CD compared_VBN to_TO a_DT score_NN of_IN 0_CD ;_: ++_NN ,_, P_NN <_SYM 0.01_CD compared_VBN to_TO a_DT score_NN of_IN 1_CD ._SENT FIG._NN 2_CD ._SENT |_SYM Comparison_NN of_IN serum_NN anti-H_NN ._SENT pylori_NNS Comparison_NN of_IN serum_NN anti-H_NN ._SENT pylori_NNS antibody_NN (_( IgG_NP )_) levels_NNS among_IN groups_NNS based_VBN on_IN grading_VBG scores_NNS of_IN four_CD histological_JJ features_NNS of_IN body_NN mucosa_NN ._SENT Scores_NNS :_: 0_CD ,_, normal_RB ;_: 1_LS ,_, mild_JJ ;_: 2_LS ,_, moderate_JJ ;_: and_CC 3_CD ,_, marked_VBD ._SENT Each_DT column_NN represents_VBZ the_DT mean_JJ +-_NN standard_JJ error_NN of_IN the_DT mean_NN ._SENT **_SYM ,_, P_NN <_SYM 0.01_CD compared_VBN to_TO a_DT score_NN of_IN 0_CD ;_: ++_NN ,_, P_NN <_SYM 0.01_CD compared_VBN to_TO a_DT score_NN of_IN 1_CD ._SENT FIG._NN 3_CD ._SENT |_SYM Distribution_NN of_IN anti-H_NP ._SENT pylori_NNS Distribution_NN of_IN anti-H_NP ._SENT pylori_NNS antibody_NN (_( IgG_NP )_) levels_NNS in_IN H._NP pylori-infected_JJ and_CC uninfected_JJ patients_NNS (_( n_NN =_SYM 169_CD )_) ._SENT TABLE_NN 1_CD |_SYM Multiple_JJ stepwise_JJ linear_JJ regression_NN analysis_NN of_IN factors_NNS correlated_VBN with_IN antibody_NN levels_NNS In_IN our_PP$ present_JJ study_NN ,_, there_EX was_VBD no_DT difference_NN in_IN antibody_NN levels_NNS of_IN the_DT normal_JJ mucosa_NN ,_, gastritis_NN ,_, and_CC duodenal_JJ ulcers_NNS in_IN H._NP pylori-infected_JJ patients_NNS ._SENT This_DT is_VBZ in_IN accordance_NN with_IN the_DT study_NN by_IN Sharma_NP et_FW al._FW ,_, who_WP reported_VBD that_IN H._NP pylori_NNS serology_NN cannot_MD be_VB used_VBN to_TO predict_VB the_DT presence_NN or_CC absence_NN of_IN gastroduodenal_JJ ulcer_NN disease_NN ._SENT Similarly_RB ,_, Sheu_NP et_FW al._FW reported_VBD no_DT difference_NN in_IN antibody_NN levels_NNS between_IN nonulcer_NN and_CC ulcer_NN subgroups_NNS ,_, and_CC Hsu_NP et_FW al._FW reported_VBD that_IN levels_NNS of_IN anti-H_NP ._SENT pylori_NNS in_IN serum_NN are_VBP not_RB predictive_JJ of_IN the_DT severity_NN of_IN macroscopic_JJ gastrointestinal_JJ damage_NN ._SENT The_DT correlation_NN between_IN anti-H_NP ._SENT pylori_NNS antibody_NN levels_NNS and_CC the_DT severity_NN of_IN histological_JJ gastritis_NN or_CC H._NP pylori_NNS density_NN has_VBZ been_VBN studied_VBN with_IN conflicting_JJ results_NNS ._SENT Significant_JJ correlation_NN was_VBD reported_VBN in_IN studies_NNS in_IN which_WDT non-H_NP ._SENT pylori-infected_JJ patients_NNS were_VBD included_VBN in_IN the_DT analysis_NN ._SENT On_IN the_DT other_JJ hand_NN ,_, no_DT such_JJ correlation_NN was_VBD found_VBN in_IN one_CD report_NN in_IN which_WDT only_JJ H._NP pylori-infected_JJ patients_NNS were_VBD analyzed_VBN ._SENT More_JJR than_IN 90_CD %_NN of_IN H._NP pylori-infected_JJ patients_NNS have_VBP detectable_JJ serum_NN IgG_NP antibodies_NNS ,_, and_CC the_DT vast_JJ majority_NN of_IN H._NP pylori-infected_JJ patients_NNS have_VBP chronic_JJ active_JJ gastritis_NN in_IN the_DT antral_JJ biopsy_NN specimens_NNS ._SENT Therefore_RB ,_, the_DT status_NN of_IN H._NP pylori_NNS infection_NN is_VBZ a_DT crucial_JJ confounding_VBG factor_NN in_IN analyzing_VBG the_DT relationship_NN between_IN antibody_NN levels_NNS and_CC histological_JJ gastritis_NN ._SENT If_IN non-H_NP ._SENT pylori-infected_JJ patients_NNS are_VBP included_VBN in_IN the_DT analysis_NN ,_, the_DT correlation_NN between_IN antibody_NN levels_NNS and_CC gastritis_NN scores_NNS or_CC H._NP pylori_NNS density_NN may_MD be_VB misleading_VBG due_JJ to_TO their_PP$ common_JJ association_NN with_IN the_DT status_NN of_IN H._NP pylori_NNS ._SENT Our_PP$ study_NN also_RB supports_VBZ these_DT observations_NNS ._SENT In_IN this_DT study_NN ,_, grades_NNS of_IN active_JJ and_CC chronic_JJ inflammation_NN ,_, atrophy_NN ,_, lymphoid_JJ follicles_NNS ,_, and_CC H._NP pylori_NNS density_NN were_VBD correlated_VBN with_IN antibody_NN levels_NNS in_IN the_DT antral_JJ mucosa_NN but_CC were_VBD not_RB correlated_VBN if_IN only_JJ H._NP pylori-infected_JJ patients_NNS were_VBD analyzed_VBN ._SENT Our_PP$ results_NNS had_VBD some_DT differences_NNS from_IN the_DT reports_NNS of_IN Hsu_NP et_FW al._FW and_CC Sheu_NP et_FW al._FW ._SENT In_IN the_DT study_NN by_IN Hsu_NP et_FW al._FW ,_, antibody_NN levels_NNS did_VBD not_RB correlate_VB with_IN grades_NNS of_IN antral_JJ mononuclear_JJ cell_NN infiltration_NN ,_, mucosal_JJ atrophy_NN ,_, or_CC intestinal_JJ metaplasia_NN but_CC did_VBD correlate_NN with_IN grades_NNS of_IN antral_JJ neutrophil_JJ infiltration_NN and_CC antral_JJ bacterial_JJ density_NN in_IN H._NP pylori-infected_JJ patients_NNS ._SENT The_DT ELISA_NP kit_NN they_PP used_VBD was_VBD the_DT same_JJ as_IN ours_PP ._SENT Since_IN anti-H_NP ._SENT pylori_NNS antibody_NN levels_NNS do_VBP not_RB show_VB a_DT normal_JJ distribution_NN ,_, logarithmic_JJ transformation_NN is_VBZ more_RBR appropriate_JJ when_WRB performing_VBG a_DT parametric_JJ test_NN ._SENT Therefore_RB ,_, the_DT variance_NN may_MD result_VB from_IN the_DT small_JJ number_NN of_IN cases_NNS in_IN their_PP$ study_NN (_( n_NN =_SYM 36_CD )_) and_CC different_JJ statistical_JJ methods_NNS ._SENT In_IN the_DT study_NN by_IN Sheu_NP et_FW al._FW ,_, antibody_NN levels_NNS correlated_VBN with_IN the_DT severity_NN of_IN acute_JJ or_CC chronic_JJ inflammation_NN ._SENT However_RB ,_, the_DT rate_NN of_IN absence_NN of_IN neutrophil_JJ infiltration_NN (_( score_NN ,_, 0_CD )_) in_IN H._NP pylori-infected_JJ patients_NNS in_IN their_PP$ study_NN was_VBD 63_CD %_NN ._SENT This_DT is_VBZ contrary_JJ to_TO the_DT well-established_JJ concept_NN that_IN the_DT majority_NN of_IN H._NP pylori-infected_JJ patients_NNS have_VBP chronic_JJ active_JJ gastritis_NN in_IN the_DT antral_JJ biopsy_NN specimens_NNS ._SENT In_IN addition_NN ,_, the_DT ANOVA_NP model_NN with_IN Duncan_NP 's_POS test_NN is_VBZ not_RB an_DT appropriate_JJ statistical_JJ method_NN for_IN data_NNS with_IN unequal_JJ numbers_NNS in_IN the_DT groups_NNS ._SENT In_IN this_DT study_NN ,_, grades_NNS of_IN active_JJ and_CC chronic_JJ inflammation_NN ,_, atrophy_NN ,_, and_CC lymphoid_JJ follicles_NNS in_IN the_DT body_NN mucosa_NN remained_VBD significantly_RB correlated_VBN with_IN antibody_NN levels_NNS in_IN H._NP pylori-infected_JJ patients_NNS ._SENT The_DT correlation_NN coefficients_NNS ,_, however_RB ,_, were_VBD reduced_VBN to_TO half_NN of_IN those_DT when_IN non-H_NP ._SENT pylori-infected_JJ patients_NNS were_VBD included_VBN ._SENT This_DT indicates_VBZ that_IN the_DT status_NN of_IN H._NP pylori_NNS infection_NN is_VBZ an_DT important_JJ contributing_JJ factor_NN ,_, which_WDT has_VBZ been_VBN demonstrated_VBN in_IN the_DT multivariate_JJ linear_JJ regression_NN model_NN ._SENT The_DT data_NNS in_IN this_DT study_NN were_VBD obtained_VBN from_IN dyspeptic_JJ patients_NNS ,_, so_RB they_PP may_MD not_RB generalize_VB to_TO asymptomatic_JJ subjects_NNS ._SENT There_EX has_VBZ been_VBN a_DT report_NN showing_VBG that_IN diffuse_JJ antral_JJ gastritis_NN with_IN prominent_JJ lymphoid_JJ follicles_NNS has_VBZ the_DT highest_JJS antibody_NN levels_NNS ._SENT However_RB ,_, in_IN that_DT study_NN ,_, no_DT statistical_JJ data_NNS were_VBD presented_VBN ,_, so_RB we_PP calculated_VBD the_DT difference_NN between_IN diffuse_JJ antral_JJ gastritis_NN and_CC chronic_JJ atrophic_JJ gastritis_NN from_IN the_DT data_NNS presented_VBN in_IN the_DT table_NN and_CC found_VBD no_DT statistical_JJ difference_NN (_( 0.274_CD +-_NN 0.025_CD versus_CC 0.266_CD +-_NN 0.013_CD [_SYM mean_JJ +-_JJ SD_NN ]_SYM ;_: P_NN =_SYM 0.757_CD )_) ._SENT In_IN our_PP$ study_NN ,_, antibody_NN levels_NNS of_IN <30_or 70_CD U/ml_NP had_VBD good_JJ predictive_JJ value_NN for_IN the_DT absence_NN or_CC presence_NN ,_, respectively_RB ,_, of_IN H._NP pylori_NNS infection_NN ._SENT For_IN individuals_NNS having_VBG a_DT value_NN between_IN 30_CD and_CC 70_CD U/ml_NN ,_, the_DT so-called_JJ gray_JJ zone_NN ,_, a_DT different_JJ diagnostic_JJ method_NN is_VBZ recommended_VBN to_TO assess_VB H._NP pylori_NNS status_NN more_JJR accurately_RB ._SENT When_WRB antibody_NN levels_NNS are_VBP >70_JJ U/ml_NP ,_, higher_JJR levels_NNS do_VBP not_RB improve_VB the_DT positive_JJ predictive_JJ value_NN ._SENT However_RB ,_, our_PP$ previous_JJ study_NN of_IN the_DT rapid_JJ serological_JJ test_NN has_VBZ demonstrated_VBN that_IN antibody_NN levels_NNS in_IN ELISA_NP are_VBP correlated_VBN with_IN the_DT density_NN of_IN the_DT reaction_NN band_NN in_IN the_DT rapid_JJ serological_JJ test_NN ._SENT The_DT higher_JJR the_DT antibody_NN levels_NNS ,_, the_DT more_RBR clearly_RB the_DT band_NN is_VBZ noted_VBN ._SENT The_DT lower_JJR the_DT antibody_NN levels_NNS ,_, the_DT more_RBR likely_JJ that_IN it_PP will_MD be_VB regarded_VBN as_RB negative_JJ in_IN the_DT rapid_JJ serological_JJ test_NN due_JJ to_TO a_DT very_RB weak_JJ color_NN change_NN of_IN the_DT reaction_NN band_NN ._SENT Thus_RB ,_, higher_JJR antibody_NN levels_NNS have_VBP a_DT favorable_JJ effect_NN on_IN the_DT diagnosis_NN of_IN H._NP pylori_NNS infection_NN in_IN rapid_JJ serological_JJ tests_NNS ._SENT There_EX were_VBD several_JJ studies_NNS demonstrating_VBG that_IN the_DT sensitivity_NN of_IN serological_JJ diagnosis_NN of_IN H._NP pylori_NNS infection_NN was_VBD higher_JJR in_IN the_DT older_JJR group_NN (_( >=45_JJ years_NNS )_) than_IN in_IN the_DT younger_JJR group_NN (_( <45_JJ years_NNS )_) ._SENT Our_PP$ study_NN showing_VBG higher_JJR antibody_NN levels_NNS in_IN the_DT older_JJR group_NN in_IN H._NP pylori-infected_JJ patients_NNS could_MD explain_VB this_DT phenomenon_NN ,_, because_IN the_DT higher_JJR the_DT antibody_NN levels_NNS ,_, the_DT fewer_JJR false_JJ negatives_NNS there_EX will_MD be_VB ._SENT In_IN conclusion_NN ,_, levels_NNS of_IN IgG_NP anti-H_NP ._SENT pylori_NNS antibody_NN in_IN the_DT serum_NN do_VBP not_RB predict_VB the_DT presence_NN of_IN macroscopic_JJ gastroduodenal_JJ diseases_NNS or_CC the_DT density_NN of_IN H._NP pylori_NNS colonization_NN in_IN H._NP pylori-infected_JJ dyspeptic_JJ patients_NNS ._SENT The_DT presence_NN of_IN H._NP pylori_NNS infection_NN ,_, higher_RBR updated_VBN Sydney_NP system_NN chronic_JJ gastritis_NN scores_NNS of_IN the_DT corpus_NN ,_, and_CC older_JJR age_NN are_VBP associated_VBN with_IN higher_JJR antibody_NN levels_NNS ._SENT Setting_VBG a_DT gray_JJ zone_NN is_VBZ necessary_JJ for_IN ELISA_NP ,_, since_IN the_DT accuracy_NN in_IN this_DT zone_NN does_VBZ not_RB allow_VB a_DT precise_JJ determination_NN of_IN H._NP pylori_NNS status_NN ._SENT 